Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+ patients over 24 months – Results from the German TAFNES cohort study

Zurück zur Übersicht

05.-08.10.2020 / HIV Drug Therapy – Glasgow

Studiensammlung zu HIV

Zur Übersicht